12:00 AM
 | 
Aug 27, 2007
 |  BioCentury  |  Tools & Techniques

Two sides to SIRT1

In the last few years, companies have started pursuing agonism of SIRT1 as a way of boosting the body's metabolism to treat Type II diabetes, while other researchers say they have evidence that activating the target might be useful in treating or preventing cancer.

But another camp is arguing that blocking, not activating, SIRT1 or other sirtuins could be used to treat cancer through the upregulation of tumor suppressor proteins. Pharmion Corp. is exploring that mechanism via last week's expanded deal with MethylGene Inc. Their 2006 deal will now include a project on selective inhibitors of SIRT1 and one or two of the six other members of the enzyme family.

Jeffrey Besterman, EVP of R&D and CSO at MethylGene (TSX:MYG, Montreal, Quebec), told BioCentury that research has only recently begun to uncover clear rationales for therapeutic inhibition of the sirtuins, which are class III histone deacetylases.

"In cancer, knockout technologies have begun to shed some light, indicating that sirtuins might make good targets," he...

Read the full 817 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >